Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial
Thirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an effective vaccine is seen as critical for the elimi...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/7/1351 |
id |
doaj-0670a10867c94be7b6a7e7ff5d2c33ab |
---|---|
record_format |
Article |
spelling |
doaj-0670a10867c94be7b6a7e7ff5d2c33ab2021-07-23T14:11:38ZengMDPI AGViruses1999-49152021-07-01131351135110.3390/v13071351Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy TrialChristopher C. Phelps0Christopher M. Walker1Jonathan R. Honegger2Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USAThirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an effective vaccine is seen as critical for the elimination of HCV. The recent failure of the first vaccine efficacy trial for the prevention of chronic HCV confirmed suspicions that this virus will be a challenging vaccine target. Here, we examine the published data from this first efficacy trial along with the earlier clinical and pre-clinical studies of the vaccine candidate and then discuss three key research directions expected to be important in ongoing and future HCV vaccine development. These include the following: 1. design of novel immunogens that generate immune responses to genetically diverse HCV genotypes and subtypes, 2. strategies to elicit broadly neutralizing antibodies against envelope glycoproteins in addition to cytotoxic and helper T cell responses, and 3. consideration of the unique immunological status of individuals most at risk for HCV infection, including those who inject drugs, in vaccine platform development and early immunogenicity trials.https://www.mdpi.com/1999-4915/13/7/1351hepatitis C virus (HCV)vaccineimmunityT cellsB cellsantibodies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christopher C. Phelps Christopher M. Walker Jonathan R. Honegger |
spellingShingle |
Christopher C. Phelps Christopher M. Walker Jonathan R. Honegger Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial Viruses hepatitis C virus (HCV) vaccine immunity T cells B cells antibodies |
author_facet |
Christopher C. Phelps Christopher M. Walker Jonathan R. Honegger |
author_sort |
Christopher C. Phelps |
title |
Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial |
title_short |
Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial |
title_full |
Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial |
title_fullStr |
Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial |
title_full_unstemmed |
Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial |
title_sort |
where to next? research directions after the first hepatitis c vaccine efficacy trial |
publisher |
MDPI AG |
series |
Viruses |
issn |
1999-4915 |
publishDate |
2021-07-01 |
description |
Thirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an effective vaccine is seen as critical for the elimination of HCV. The recent failure of the first vaccine efficacy trial for the prevention of chronic HCV confirmed suspicions that this virus will be a challenging vaccine target. Here, we examine the published data from this first efficacy trial along with the earlier clinical and pre-clinical studies of the vaccine candidate and then discuss three key research directions expected to be important in ongoing and future HCV vaccine development. These include the following: 1. design of novel immunogens that generate immune responses to genetically diverse HCV genotypes and subtypes, 2. strategies to elicit broadly neutralizing antibodies against envelope glycoproteins in addition to cytotoxic and helper T cell responses, and 3. consideration of the unique immunological status of individuals most at risk for HCV infection, including those who inject drugs, in vaccine platform development and early immunogenicity trials. |
topic |
hepatitis C virus (HCV) vaccine immunity T cells B cells antibodies |
url |
https://www.mdpi.com/1999-4915/13/7/1351 |
work_keys_str_mv |
AT christophercphelps wheretonextresearchdirectionsafterthefirsthepatitiscvaccineefficacytrial AT christophermwalker wheretonextresearchdirectionsafterthefirsthepatitiscvaccineefficacytrial AT jonathanrhonegger wheretonextresearchdirectionsafterthefirsthepatitiscvaccineefficacytrial |
_version_ |
1721285363537805312 |